双靶点BCL2/BCL-XL抑制剂AZD0466在急性淋巴细胞白血病临床前模型中的抗白血病疗效
该临床前研究分析了BCL2与BCL-XL在B-ALL和T-ALL中的表达差异,并评估了双靶点抑制剂AZD0466与BCL2抑制剂维奈克拉的疗效。结果显示B-ALL以BCL2高表达为主且对维奈克拉或AZD4320敏感,而T-ALL呈BCL-XL强表达且对双靶点抑制敏感;在T-ALL小鼠模型中,AZD0466而非维奈克拉可减少白血病负荷并延长生存且无明显毒性。作者认为AZD0466在T-ALL中优于单靶点BCL2抑制,并支持将双靶点BCL2/BCL-XL抑制剂单用或联合标准化疗及免疫治疗推进至ALL临床试验。
要点
- B-ALL以BCL2高表达为主,对维奈克拉或AZD4320敏感。
- T-ALL呈BCL-XL强表达,对双靶点BCL2/BCL-XL抑制敏感。
- T-ALL小鼠模型中AZD0466而非维奈克拉减少白血病负荷并延长生存。
核心结论
- 作者认为新型双靶点BCL2/BCL-XL抑制剂AZD0466在T-ALL中疗效优于维奈克拉单靶点BCL2抑制。
- 作者认为这些发现有助于将双靶点BCL2/BCL-XL抑制剂单用或联合标准化疗及免疫治疗推进至ALL临床试验。
研究设计与样本
- 临床前研究,分析ALL细胞系与原代样本中BCL2、BCL-XL基因表达及蛋白表达模式。
- 以AZD0466(AZD4320的药物-树枝状聚合物偶联物)和维奈克拉(ABT-199)进行活性与敏感性分析,并以BH3 profiling验证依赖性。
- 在T-ALL小鼠模型中评估AZD0466与维奈克拉对白血病负荷及生存的影响。
主要发现
- 基因表达与活性分析结合ALL细胞系及原代样本蛋白表达模式显示,B-ALL中BCL2表达升高,对维奈克拉或AZD4320高度敏感。
- T-ALL样本中观察到BCL-XL强表达及对双靶点BCL2/BCL-XL抑制的敏感性。
- BH3 profiling证实T-ALL存在BCL2/BCL-XL共同依赖,B-ALL为BCL2依赖。
- T-ALL小鼠模型中,AZD0466而非维奈克拉减少白血病负荷并延长生存,且无明显毒性。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文为临床前研究,结果基于ALL细胞系、原代样本及T-ALL小鼠模型,尚需临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The upregulation of B-cell lymphoma 2 (BCL2) and B-cell lymphoma-extra large (BCL-XL), 2 proteins in the BCL2 family of proteins, leads to a disproportional expression of prodeath and prosurvival proteins in favor of leukemia survival, tumorigenesis, and chemoresistance. In different subsets of acute lymphoblastic leukemia (ALL), the proportion of these 2 proteins varies, and their potential as therapeutic targets needs detailed characterization. Here, we investigated BCL2 and BCL-XL, the genes that encode BCL2 and BCL-XL, and their expression differences between B-cell acute lymphoblastic leukemia (B-ALL) and T-cell ALL (T-ALL). We also evaluated the therapeutic potential of targeting these proteins with AZD0466, a novel drug-dendrimer conjugate of the BCL2/BCL-XL inhibitor AZD4320, and with BCL2 inhibitor venetoclax (ABT-199). Gene expression and activity analyses supported by the protein expression patterns in ALL cell lines and primary samples demonstrated increased levels of BCL2 expression in B-ALL, with high sensitivity to venetoclax or AZD4320. In contrast, strong BCL-XL expression and sensitivity to dual BCL2/BCL-XL inhibition was observed specifically in T-ALL samples. This observation was confirmed by BH3 profiling, demonstrating BCL2/BCL-XL codependence in T-ALL and BCL2 dependence in B-ALL. In a mouse model of T-ALL, AZD0466 but not venetoclax reduced leukemic burden and prolonged survival without significant toxicities. Our findings therefore suggest that the novel dual BCL2/BCL-XL inhibitor AZD0466 outperforms single BCL2 inhibition by venetoclax in T-ALL. These findings facilitate the translation of dual BCL2/BCL-XL inhibitors into ALL clinical trials, either alone or in combination with standard-of-care chemotherapy and immune therapies.
引用
- Kannan S, Li Y, Baran N, et al. Antileukemia efficacy of the dual BCL2/BCL-XL inhibitor AZD0466 in acute lymphoblastic leukemia preclinical models. Blood Adv. 2025. PMID: 39561378. doi:10.1182/bloodadvances.2024013423
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。